Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The United Laboratories International Holdings ( (HK:3933) ) has provided an update.
The United Laboratories International Holdings has called its annual general meeting for 23 June 2026 in Hong Kong, where shareholders will review and adopt the audited financial statements and directors’ and auditor’s reports for the year ended 31 December 2025, and consider a proposed final dividend. The meeting will also vote on the re-election of two executive directors and one independent non-executive director, the reappointment of Deloitte Touche Tohmatsu as auditor, and a mandate allowing the board to issue up to 20% of existing share capital, potentially expanded by shares repurchased, providing the company with flexibility for future capital-raising and corporate actions.
The most recent analyst rating on (HK:3933) stock is a Buy with a HK$20.00 price target. To see the full list of analyst forecasts on The United Laboratories International Holdings stock, see the HK:3933 Stock Forecast page.
More about The United Laboratories International Holdings
The United Laboratories International Holdings Limited is a pharmaceutical company incorporated in the Cayman Islands and listed in Hong Kong. The group focuses on manufacturing and distributing pharmaceutical products, operating primarily in Hong Kong and mainland China, and is overseen by a board comprising executive and independent non-executive directors.
Average Trading Volume: 10,967,076
Technical Sentiment Signal: Hold
Current Market Cap: HK$18.82B
See more data about 3933 stock on TipRanks’ Stock Analysis page.